Prosecution Insights
Last updated: April 19, 2026

Kalvista Pharmaceuticals Limited

6 pending office actions

Portfolio Summary

6
Total Pending OAs
2
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18264810 TREATMENTS OF HEREDITARY ANGIOEDEMA ROZOF, TIMOTHY R 1625 Non-Final OA Aug 09, 2023
18347815 POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1-({4-[(2-OXOPYRIDIN-1-YL)METHYL]PHENYL}METHYL)PYRAZOLE-4-CARBOXAMIDE AND SALTS THEREOF CHANDRAKUMAR, NIZAL S 1625 Final Rejection Jul 06, 2023
17634593 ENZYME INHIBITORS ANDERSON, REBECCA L 1626 Non-Final OA Feb 11, 2022
17633973 ENZYME INHIBITORS THOMAS, TIMOTHY P 1614 Non-Final OA Feb 09, 2022
17633980 ENZYME INHIBITORS HIRAKIS, SOPHIA P 1623 Non-Final OA Feb 09, 2022
17617439 TREATMENTS OF HEREDITARY ANGIOEDEMA HIBSHMAN, SARAH GRACE 1693 Final Rejection Dec 08, 2021

Managing Kalvista Pharmaceuticals Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month